Hoth Therapeutics

About:

Hoth Therapeutics is a clinical-stage biopharmaceutical company focusing on developing new therapies for dermatological disorders.

Website: https://www.hoththerapeutics.com

Twitter/X: hothinc

Description:

​Hoth Therapeutics is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. biopharmaceutical company focused on developing new generation therapies for dermatological disorders. HOTH’s pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth recently entered into a Joint Development Agreement to further the development of vaccine prospects to prevent, intercept or treat the Coronavirus (COVID-19) based upon VaxCelerate, a self-assembling vaccine (SAV) platform exclusively licensed by Voltron from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH).

Total Funding Amount:

$45.6M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

New York, New York, United States

Founded Date:

2017-01-01

Founders:

Robb Knie

Number of Employees:

1-10

Last Funding Date:

2023-09-13

IPO Status:

Public

Industries:

© 2025 bioDAO.ai